AMDX-2011P
Phase 2Small molecule
AMDX-2011P is one of 122 small molecule programs targeting Glaucoma. It is currently in Phase 2.
3
Indications
3
Total Trials
3
Active Trials
121
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
91 competitors in Alzheimer Disease
#DrugCompanyPhaseTrials
1Thalomid
Bristol-Myers SquibbApproved
Soriatane
GSKApproved
Minipress
PfizerApproved
Marinol
Jazz PharmaceuticalsApproved
Lexapro
AbbVieApproved
Calciferol
Jazz PharmaceuticalsApproved
Azilect
TevaApproved
Neupro
UCBApproved
Evista
Eli LillyApproved
Niacor
AbbVieApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AMDX-2011P. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAmydis Inc.